Last $167.00 USD
Change Today +0.27 / 0.16%
Volume 95.6K
ILMN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 10:01 AM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5200 Illumina Way

San Diego, CA 92122

United States

Phone: 858-202-4500

Fax: 858-202-4766

Illumina, Inc. operates as a developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. The company, using its proprietary technologies, provides sequencing- and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company’s portfolio of systems, consumables, and analysis tools are designed to simplify genetic analysis. Its sequencing instruments could be used to perform a range of nucleic acid (DNA and RNA) analyses on various samples. The company’s array-based solutions provide ideal tools to perform genome-wide association studies (GWAS) involving single-nucleotide polymorphism, genotyping and copy number variation analyses, as well as gene expression profiling, and other DNA and RNA studies. To provide the company’s customers with sample-to-answer workflow solutions, it acquired NextBio, which provides clinical and genomic informatics in November 2013; Advanced Liquid Logic Inc., which provides digital microfluidics and liquid handling solutions in July 2013; and Epicentre Technologies Corporation, a provider of nucleic acid sample preparation reagents and specialty enzymes for sequencing and microarray applications. Products The company’s products give its customers the ability to analyze the genome at any level of complexity, from whole-genome sequencing to targeted panels, and enable the company to serve various markets, including research, agriculture, reproductive and genetic health, oncology, pharmaceuticals, commercial molecular diagnostic, and consumer genomics companies. The majority of its product sales consist of instruments and consumables (which include reagents, flow cells, and BeadChips) based on its proprietary technologies. Sequencing Platforms Based on the company’s proprietary SBS technology, its next-generation sequencing platforms are designed to meet the workflow, output, and accuracy demands of a range of sequencing applications. Its sequencing platforms could generate between 500 Mb and 1.8 Tb of genomic data, depending on the instrument and application, at different price points per Gb and for different applications ranging from small genome, amplicon, and targeted gene panel sequencing to population-scale whole human genome sequencing. Array Platforms The HiScan and iScan Systems are dedicated array scanners that support the sensitive imaging of the company’s array-based genetic analysis products. They incorporate lasers, optics, and detection systems, delivering sub-micron resolution and unmatched throughput rates. The HiScan and iScan support its Infinium, GoldenGate, DASL, gene expression, and methylation assays. Consumables The company has developed various sample preparation and sequencing kits to simplify workflows and accelerate analysis. Its sequencing applications include whole-genome sequencing kits, which enable sequencing of entire genomes of any size and complexity, and targeted resequencing kits, which enable sequencing of exomes, specific genes, or other genomic regions of interest. Through its acquisition of Epicentre Technologies Corporation, the company owns the proprietary Nextera technology for next-generation sequencing library preparation. This technology has enabled the company to offer sequencing library preparation kits with lower sample input requirements that simplify genetic analysis workflows and reduce the time from sample preparation to answer. The company’s array-based genotyping consumables enable customers to perform a range of analyses, including analyzing diversity across a species, disease-related mutations, and genetic characteristics associated with cancer. Customers might select from a range of human, animal, and agriculturally relevant genome panels or create their own custom arrays that could be used to

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILMN:US $167.00 USD +0.27

ILMN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $56.11 USD +0.08
Avago Technologies Ltd $69.97 USD +0.09
Becton Dickinson and Co $118.87 USD +0.01
QIAGEN NV €18.56 EUR -0.075
Waters Corp $105.06 USD -0.10
View Industry Companies
 

Industry Analysis

ILMN

Industry Average

Valuation ILMN Industry Range
Price/Earnings 100.0x
Price/Sales 13.5x
Price/Book 20.2x
Price/Cash Flow 83.6x
TEV/Sales 11.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.